Cagrilintide + Semaglutide: The Composition Stack

The cagrilintide and semaglutide fixed-dose combination is the most discussed body-composition stack in the GLP-1 pipeline as of mid-2026. It is investigational. It is not currently approved. The phase 3 readouts that have appeared so far are striking enough to make the eventual approval decision one of the most consequential events on the obesity-pharmacology calendar — and the body-composition story is the part that most differentiates this combination from the current GLP-1 class.

This article explains what cagrilintide is, what the combination changes mechanistically, what the trial data shows about fat mass versus lean mass loss, and what TelePeptide's prescribing position is on a combination that is not yet on the market.

What cagrilintide is

Cagrilintide is a long-acting analog of amylin. Amylin is a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells. Native amylin has a very short half-life and is not practical as a therapeutic. Cagrilintide modifies the structure to extend the duration of action sufficiently to allow once-weekly subcutaneous administration, similar in dosing cadence to semaglutide.

Amylin acts primarily through receptors in the hindbrain, particularly the area postrema and nucleus tractus solitarius. The downstream effects are:

1. Slowed gastric emptying. This contributes to early postprandial satiety.
2. Increased meal-related satiety. The signal is mediated centrally and reduces the volume of food consumed at a meal as well as the frequency of subsequent eating episodes.
3. Reduced postprandial glucagon secretion. This contributes to glycemic control by limiting hepatic glucose output after a meal.
4. Possible effects on energy expenditure. This is the part that is most relevant for the body-composition story and the part that is least mechanistically settled.

GLP-1 agonism shares the gastric-emptying and satiety effects but operates through a different receptor and a partly different central network. Adding amylin to GLP-1 is, in principle, additive at the satiety level and complementary at the body-composition level.

Why a stack changes body composition outcomes

Weight loss from any caloric-deficit intervention — pharmacological or dietary — is not entirely fat. Some of it is lean mass: muscle, organ tissue, and water associated with glycogen stores. The proportion of weight loss that is lean rather than fat depends on the intervention.

For GLP-1 monotherapy, body-composition substudies have generally found that approximately 25 to 40 percent of the weight lost during a typical 68-to-72-week trial is lean mass. The exact figure varies by trial, population, baseline body composition, and whether resistance training is part of the intervention. The headline weight-loss number does not break this out, but for patients whose goal is body composition rather than weight per se, lean mass loss is a meaningful cost.

The cagrilintide-semaglutide combination appears to shift this distribution. In phase 3 readouts, the combination produced not only greater total weight loss than semaglutide monotherapy but also a more favorable fat-to-lean ratio in the weight that was lost. The DXA-substudy data indicates a greater proportion of fat-mass loss and a relatively preserved lean-mass component versus monotherapy.

The mechanism is not fully resolved. Three plausible contributors:

1. Amylin-mediated effects on energy expenditure. Animal and early human data suggests amylin signaling supports basal energy expenditure, which would shift the composition of weight loss toward fat.
2. Reduced muscle protein catabolism via better satiety regulation. Tighter control of energy intake variance — fewer large deficits punctuated by overshoots — may reduce the catabolic stress on lean tissue.
3. Direct receptor effects on adipose and skeletal muscle. Both amylin and GLP-1 receptor expression has been described in skeletal muscle and adipose tissue, though the functional significance is still being characterized.

The clinically relevant point is that the combination is the first GLP-1-class regimen with body-composition data that meaningfully separates from GLP-1 monotherapy. For body-recomposition-focused patients, this is a different value proposition than a regimen that simply produces more weight loss.

What the phase 3 data shows

The cagrilintide-semaglutide fixed-dose combination has been studied in the REDEFINE phase 3 program. Readouts have been reported across multiple sub-trials covering obesity (REDEFINE 1), obesity with cardiovascular disease (REDEFINE 2), obesity with type 2 diabetes (REDEFINE 3), and other populations. Key takeaways from the readouts available as of mid-2026:

• Total weight loss. The combination produced mean weight reductions in the range of approximately 22 to 23 percent at the highest dose tested at 68 weeks, versus approximately 16 percent for semaglutide monotherapy and approximately 11 to 12 percent for cagrilintide monotherapy in head-to-head arms.
• Body composition. DXA substudy data indicates that the additional weight loss in the combination arm is preferentially fat mass. The lean-mass loss component is comparable to or modestly lower than semaglutide alone in absolute terms, despite greater total weight loss.
• Glycemic control. In the diabetes arm, the combination produced greater HbA1c reductions than either monotherapy.
• Cardiovascular markers. Reductions in waist circumference, blood pressure, and lipid markers were greater in the combination arm than in either monotherapy arm.

These readouts are positive on the metrics that matter for both weight management and metabolic health. The remaining gating items are the formal regulatory submission, FDA review timeline, and pharmacy supply once approval occurs.

Side effects and tolerability

The reported tolerability profile for the combination is qualitatively similar to semaglutide monotherapy. The dominant side effects are gastrointestinal — nausea, vomiting, diarrhea, and constipation — concentrated in the dose-escalation phase and largely resolving with continued treatment. The discontinuation rate due to adverse events in the phase 3 readouts has been within the range expected for a GLP-1-class therapy.

Two specific tolerability points are worth noting:

1. Slightly higher GI event rate than monotherapy. This is consistent with the additive effect of amylin on gastric emptying. The increment is modest but present.
2. Heart rate. Mean heart rate increases of a few beats per minute have been reported, consistent with the GLP-1 component. This is not unique to the combination; it is a class effect.

The risk profile is meaningfully better-characterized than for some other late-stage pipeline compounds, because two of the three components are individually well-studied (semaglutide is approved across multiple indications, and cagrilintide monotherapy has its own dataset). The combination still requires its own approval pathway, but the underlying pharmacology is not new territory.

Where the FDA pipeline sits in 2026

As of mid-2026 the cagrilintide-semaglutide combination is investigational. The phase 3 program has produced positive readouts. The path to FDA review and decision is on the calendar but not complete. Public timeline guidance from the sponsor places approval decisions in the next 12 to 18 months for the lead obesity indication, with diabetes and cardiovascular indications likely to follow on a separate timeline.

What this means for prescribing now:

• No legitimate prescriber has access to an approved cagrilintide-semaglutide combination as a finished pharmaceutical product. Any source claiming otherwise is misrepresenting the regulatory status.
• Compounded substitutes are not equivalent. Combination products composed by a compounding pharmacy from individual constituents are not the same regulatory or pharmaceutical object as an approved fixed-dose combination, and TelePeptide does not prescribe them.
• The right action right now is to be informed and to wait. Patients on semaglutide monotherapy who are interested in the combination can continue their current treatment and revisit the question once approval and pharmacy supply are in place. There is no clinical urgency to switch into an investigational regimen.

How TelePeptide will handle the combination after approval

When the cagrilintide-semaglutide combination is approved, prescribing through TelePeptide will follow the same model used for currently approved GLP-1-class agents:

1. Clinical eligibility review. BMI thresholds, comorbidity context, contraindications, and medication interactions are reviewed by the prescribing clinician.
2. Pharmacy supply through approved channels. TelePeptide does not prescribe compounded versions of approved combinations.
3. Body-composition tracking. For patients whose goal is body recomposition rather than weight per se, we will offer DXA-based or similar body-composition tracking as part of the protocol where appropriate.
4. Resistance training and protein-intake guidance. Lean-mass retention during weight loss is partly pharmacological and partly behavioral. The combination shifts the curve, but resistance training and adequate protein intake remain the dominant levers for lean-mass preservation.

The combination is likely to be a meaningful addition to the prescribing landscape because it changes the body-composition equation rather than only the weight-loss number. For patients whose definition of success is body composition, this is a different category of intervention.

What to track between now and approval

For patients and prescribers following this compound, the items worth tracking through the next year:

• FDA decision timing for the lead obesity indication. This is the gating event for legitimate prescribing access.
• Cardiovascular outcome trial readouts. These determine whether the indication will extend beyond weight management into cardiovascular risk reduction.
• Pricing and pharmacy distribution model. Combination biologics are typically priced higher than the components separately. The economic position of the combination in the market will affect access.
• Long-term tolerability and durability data. Phase 3 trials run 68 to 72 weeks. Real-world durability and tolerability beyond two years will accumulate after approval.

TelePeptide publishes pipeline updates quarterly. The next FDA peptide watchlist update will include the latest approval-timing guidance for this combination and the rest of the late-stage GLP-1 pipeline.

Bottom line

The cagrilintide-semaglutide combination is the first GLP-1-class regimen with body-composition data that materially differentiates from monotherapy. The phase 3 readouts are positive both on total weight loss and on fat-to-lean ratio. It is not yet approved. The right position is to be informed, to wait for approval, and to revisit the prescribing question through legitimate pharmacy channels at that point.

For patients currently on semaglutide monotherapy and interested in the combination, the practical path is to continue current treatment, track lean mass through whatever body-composition method is available, and reconsider the regimen once the approved product is on the market.